AND SPECIFIC AIMS: NETWORK RESOURCE This component of the Mayo Clinic PGRN renewal application represents a request for the funding of a """"""""Network Resource"""""""" designed to provide the entire PGRN with access to the latest techniques In the rapidly evolving field of """"""""Next Generation"""""""" DNA sequencing. Access would be provided through a recurring, peer-reviewed process available to all PGRN Centers similar to the current """"""""PGRN-RIKEN"""""""" process for obtaining access to pharmacogenomic GWAS genotyping through the PGRN-RIKEN collaboration. This proposed """"""""PGRN Nehwork Resource"""""""" is one of three coordinated applications from current PGRN Centers, all with similar goals - clearly indicating an unmet need in pharmacogenomic research - a need emphasized by the letters of support from current PGRN Centers that are attached to this application. Those letters were sent by eight different PGRN research centers. Although pharmacoqenomics has always required access to DNA sequencing, that need has been accentuated bv recent dramatic changes in DNA seguencing technology and bv the eguallv dramatic outcomes of the application of genome-wide approaches to pharmacogenomics. Each of these proposals is designed to provide a """"""""link"""""""" between the PGRN and a large, experienced Genomics Center with expertise in both the application and the evaluation of DNA sequencing technology. The issue is not whether pharmacogenomics as a discipline requires access to the very latest in rapidly evolving DNA sequencing techniques, but only how to achieve that goal in a way that will best advance the science while being affordable and open to all PGRN Centers. Specifically, the Mayo PGRN is proposing that a formal collaborative relationship be established with the Baylor College of Medicine (BCM)-Human Genome Sequencing Center (HGSC), one of three NHGRIsupported large genome centers - with an open, protocol-based selection process similar to the well established and highly successful PGRN-RIKEN process for the selection of PGRN pharmacogenomic GWAS genotyping projects performed in collaboration with RIKEN. The initial focus of the Mayo PGRN-sponsored """"""""Next Generation"""""""" DNA sequencing Network Resource would be on sequencing large contiguous regions of the genome. In some cases, this will involve complete resequencing of large genes or tandemly repeated gene families or even entire gene families, e.g., the """"""""CYPome"""""""", all cytochrome P450 genes. In other cases, it wilt involve focused resequencing across """"""""SNP signals"""""""" observed during pharmacogenomic GWA studies - in many cases, GWA studies made possible by the PGRN-RIKEN collaboration, thus building on a foundation established by that very successful program. Since the review panel for these applications will evaluate a series of Network Resource applications for access to Next Generation DNA sequencing, it should be emphasized that the Mayo PGRN looks upon these efforts as complementary. Therefore, it is possible that reviewers may conclude that some """"""""combination"""""""" of these proposals should be supported. All of these proposals share; ? A recognition of the critical need for access to rapidly evolving DNA sequencing techniques in order to advance the science of pharmacogenomics. ? A recognition that established Genome Centers have the requisite experience, expertise and infrastructure required to make this effort succeed. ? A recognition that the """"""""process"""""""" for access to Next Generation DNA sequencing will have to be open to all PGRN centers, based on scientific significance and feasibility. The cost associated with these studies would be covered primarily by funding available to the """"""""Network Resource"""""""".

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19GM061388-15
Application #
8683187
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ho, Ada Man-Choi; Qiu, Yanyan; Jia, Yun-Fang et al. (2016) Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. Alcohol Clin Exp Res 40:1531-9
Tamm, Riin; Mägi, Reedik; Tremmel, Roman et al. (2016) Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther :
Ingle, James N; Xie, Fang; Ellis, Matthew J et al. (2016) Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Res 76:7012-7023
Aziz, Ayesha; Kawamoto, Kensaku; Eilbeck, Karen et al. (2016) The genomic CDS sandbox: An assessment among domain experts. J Biomed Inform 60:84-94
Cairns, Junmei; Ung, Choong Yong; da Rocha, Edroaldo Lummertz et al. (2016) A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. Sci Rep 6:37003
Chapman, Judith-Anne W; Shepherd, Lois E; Ingle, James N et al. (2016) Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Res Treat 156:343-9
Caraballo, Pedro J; Hodge, Lucy S; Bielinski, Suzette J et al. (2016) Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med :
Deng, Min; Yang, Xu; Qin, Bo et al. (2016) Deubiquitination and Activation of AMPK by USP10. Mol Cell 61:614-24
Park, Jae-Hyun; Jang, Miran; Tarhan, Yunus Emre et al. (2016) Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol 49:471-8
Kalman, L V; Agúndez, Jag; Appell, M Lindqvist et al. (2016) Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 99:172-85

Showing the most recent 10 out of 122 publications